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apies. Preferably, we  do this is in a multidisciplinary approach.This issue of Vaccine is dedicated to the Fifth ESWI Inﬂuenza
onference, held in the Latvian capital of Riga, from 14 to 17
eptember 2014. Since its ﬁrst edition in 2002, the ESWI Inﬂuenza
onferences have grown into the largest European scientiﬁc confer-
nces entirely dedicated to inﬂuenza. In keeping with its excellent
cientiﬁc reputation, the ﬁfth edition has given the ﬂoor to the
ost renowned inﬂuenza scientists in order to showcase recent
dvances in basic science and the control and prevention of
nﬂuenza, to stimulate the scientiﬁc debate on novel, unpublished
esearch data and to advance our understanding of inﬂuenza by
dentifying new research routes. ESWI does not only focus on bring-
ng scientists together to share top-level scientiﬁc data and state of
he art knowledge. Also top-level policy makers attend the con-
erences, participating in the Science Policy Interface programme,
 tailor-made track of seven sessions covering the broad ﬁeld of
nﬂuenza. To build a bridge between science and the audience and
o stimulate debate and interaction in the Science Policy Interface
essions, ESWI introduced the Reﬂection Teams, these are teams of
ommenters, who reﬂected on the session’s content and Q&A from
heir expertise and knowledge. Reﬂection Teams had been differ-
ntly composed every session and included public health ofﬁcials,
ealthcare professionals, scientiﬁc experts from a different domain,
ournalists.
Discussions at the conference had been opened by Tonio Borg,
uropean Commissioner for Health and Consumer Policy, who
mphasized the importance of inﬂuenza prevention. “The con-
inued focus on the promotion of vaccination as a key public
ealth tool is both welcome and timely,” Mr.  Borg said. This
tatement was at the heart of the Fifth ESWI Inﬂuenza Con-
erence. Indeed, remarkable examples of collaboration between
arious stakeholder groups and their positive impact on pub-
ic health were presented and discussed, demonstrating the key
mportance of interacting with stakeholders and managing the
ialogue.
The Multiparty Group for Advice on Science (MUGAS) Founda-
ion offered a groundbreaking satellite symposium on the review
nd statistical analysis of oseltamivir data. The aim of the MUGAS
oundation was to offer a thorough, independent and transparent
eta-analysis of published and unpublished data from clinical tri-
ls, carried during the procedure of licensure of the neuraminidase
nhibitors. Preliminary results of the meta-analysis were pre-
ented by Joanna Dobson (London School of Hygiene and Tropical
ttp://dx.doi.org/10.1016/j.vaccine.2015.07.001
264-410X/© 2015 Published by Elsevier Ltd.Medicine, UK). Her team had been given access to all the requested
reports and datasets, including the Individual Patient Data. The
results of the analysis indicate a highly signiﬁcant reduction in time
to alleviation of major symptoms of inﬂuenza. There was also a
highly signiﬁcant reduction in lower respiratory infections requir-
ing antibiotics. The study results have now been published in The
Lancet.
Clearly, the emergence of the H7N9 and H10N8 inﬂuenza viruses
and the continued threat of H5N1, have emphasized the unpre-
dictable and global character of inﬂuenza outbreaks. To cope with
a future pandemic outbreak of inﬂuenza, heightened readiness is
needed on a global scale. In the aftermath of the H1N1-pandemic,
however, WHO  revised its pandemic response strategy. The revi-
sion is inspired by demands for national ﬂexibility. The new
approach encourages this ﬂexibility by basing national actions on
risk assessment, resources and needs. But at the same time, some
mechanisms remain unclear. For example, vaccines will not be
ready on time unless there is an effective mechanism informing
companies to switch production from seasonal to pandemic vac-
cines. Obtaining clarity is urgent.
The global character of inﬂuenza outbreaks brings us to another
interesting point of attention: outbreak prevention and control
in developing countries. The Fifth ESWI Inﬂuenza Conference
addressed this topic extensively in a session dedicated to mater-
nal immunization, focussing on drivers and barriers in low-income
countries. This session was  made possible thanks to the speciﬁc
support of the Bill & Melinda Gates Foundation.
In conclusion, we can say that the Fifth ESWI Inﬂuenza Confer-
ence provided an accurate picture of the challenges in the inﬂuenza
ﬁeld. There is, for instance, a great need of new vaccines that pro-
tect against a broader range of inﬂuenza virus strains. Investing in
vaccine development is therefore key, not only against inﬂuenza
but also against other infectious diseases, notably against Ebola.
After all, it is striking to note that several years ago, we were on
the verge of developing a preventive medicine or a treatment for
Ebola. But we  did not. We  are equally ill-prepared when it comes
to Rift Valley Fever, MERS CoV and rabies. So now is the time to
invest in research and to develop candidate vaccines and ther-After all, emerging and re-emerging infectious clearly demon-
strate that human, animal and ecosystem health are inextricably
linked.
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